ClinicalTrials.gg
Not yet recruitingNCT07947069Updated Nov 18, 2026

Nebulized Plus Intravenous Versus Intravenous Furosemide in Pulmonary Edema

A Phase 4 interventional study of Nebulized furosemide and Intravenous furosemide in Pulmonary Edema, sponsored by Federal Government Polyclinic - Post Graduate Medical Institute (FGPC-PGMI). Not yet recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 94 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Federal Government Polyclinic - Post Graduate Medical Institute (FGPC-PGMI) · Phase 4, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years to 94 Years
Sex
All
01

Study summary

This randomized controlled trial compares intravenous furosemide alone with intravenous plus nebulized furosemide in adults with acute pulmonary edema. The main outcome is the change in peripheral oxygen saturation (SpO2) from baseline, and the secondary outcome is the change in dyspnea severity on a 0-10 visual analogue scale. The trial will test whether adding nebulized furosemide to standard intravenous furosemide gives additional benefit.

Read the detailed description

Pulmonary edema is a medical emergency in which fluid collects in the alveolar spaces, impairing gas exchange and causing respiratory distress. Intravenous furosemide is the mainstay of treatment but may cause hypotension, electrolyte imbalance and renal dysfunction. Nebulized furosemide delivers the drug directly to the lungs and may improve dyspnea and oxygenation through local effects. Most available studies have tested nebulized furosemide as an alternative to intravenous therapy rather than as an adjunct, so it remains unclear whether the combination offers added benefit over intravenous furosemide alone.

Methods: A randomized controlled trial will be conducted in the Department of Medicine, Federal Government Polyclinic Hospital, Islamabad, over 6 months after ethical approval, using non-probability consecutive sampling. A total of 130 patients (65 per group) will be enrolled. Sample size was calculated with the WHO formula for two means (alpha 0.05, power 80%, SD 1.5, expected difference 0.7) based on Barzegari et al. (2021). After written informed consent, baseline demographics, vital signs, SpO2 and dyspnea VAS score will be recorded. All patients will receive standard initial care with oxygen 6 to 10 L/min by face mask, intravenous nitroglycerin infusion starting at 10 µg/min and intravenous morphine 3 to 5 mg. Patients will be randomized 1:1 using a computer-generated sequence with sequentially numbered, opaque, sealed envelopes. Group A will receive intravenous furosemide 1 mg/kg plus nebulized furosemide 40 mg in 4 ml 0.9% saline, and Group B will receive intravenous furosemide 1 mg/kg alone. SpO2 and dyspnea VAS will be recorded at baseline and at 30, 60 and 120 minutes after intervention.

Statistical analysis: Data will be analyzed in SPSS version 23. Continuous variables will be presented as mean and standard deviation. Between-group comparison of change from baseline in SpO2 and VAS will be done with the independent samples t-test, or the Mann-Whitney U test for non-normal data. Baseline SpO2, baseline dyspnea score, oxygen flow rate, use of nitrates or morphine and underlying cardiac function will be recorded as potential confounders. A p-value below 0.05 will be considered significant.

02

Conditions studied

  • Pulmonary Edema

Keywords

  • Furosemide
  • Nebulized furosemide
  • Acute pulmonary edema
  • Oxygen saturation
  • Dyspnea
03

In context

Pulmonary Edema

126 studies on the registry are indexed under Pulmonary Edema; 27 are open to participants now.

This study's planned enrollment of 130 is above the median of 65 across 62 interventional studies indexed under Pulmonary Edema.

Browse Pulmonary Edema studies →

Lead sponsor

This is the only study on the registry with Federal Government Polyclinic - Post Graduate Medical Institute (FGPC-PGMI) as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 94 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 94 years
  • Acute shortness of breath within the past 6 hours
  • Clinical features of pulmonary edema (tachypnea, use of accessory muscles, crepitations, wheeze, gallop rhythm) with chest X-ray showing bilateral pulmonary infiltrates consistent with pulmonary edema, with or without cardiomegaly, pulmonary vascular congestion, Kerley B lines or pleural effusion

Exclusion criteria

Exclusion Criteria:

  • Cardiogenic shock or systolic blood pressure below 90 mm Hg
  • Need for intubation, cardiac arrhythmia or liver failure
  • or asthma exacerbation
  • End-stage renal disease on dialysis
  • Allergy to furosemide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    Group A: IV plus nebulized furosemide

    Intravenous furosemide 1 mg/kg slow push over 5 minutes plus nebulized furosemide 40 mg diluted in 4 ml 0.9% saline over 15 minutes, in addition to standard initial care (oxygen 6 to 10 L/min by face mask, intravenous nitroglycerin infusion starting at 10 µg/min and intravenous morphine 3 to 5 mg).

    Drug: Nebulized furosemide · Drug: Intravenous furosemide

  • Active comparator
    Group B: IV furosemide

    Intravenous furosemide 1 mg/kg slow push over 5 minutes, in addition to standard initial care (oxygen 6 to 10 L/min by face mask, intravenous nitroglycerin infusion starting at 10 µg/min and intravenous morphine 3 to 5 mg).

    Drug: Intravenous furosemide

Interventions

  • DrugNebulized furosemide

    Furosemide 40 mg diluted in 4 ml 0.9% saline given by jet nebulizer over 15 minutes.

    Also known as: Lasix

  • DrugIntravenous furosemide

    Furosemide 1 mg/kg given as a slow intravenous push over 5 minutes.

    Also known as: Lasix

06

What researchers measure

Primary outcomes

  1. Change in peripheral oxygen saturation (SpO2)

    SpO2 (%) measured with a calibrated pulse oximeter; change from baseline will be compared between groups.

    Time frame: Baseline, 30, 60 and 120 minutes after intervention (primary comparison at 60 minutes)

Secondary outcomes

  1. Change in dyspnea severity on Visual Analogue Scale (VAS)

    Patient-rated breathlessness on a 0-10 VAS (0 = no breathlessness, 10 = worst breathlessness); change from baseline will be compared between groups.

    Time frame: Baseline, 30, 60 and 120 minutes after intervention

07

Study locations

1 site
  • Department of Medicine, Federal Government Polyclinic Hospital
    Islamabad, Islamabad 44000, Pakistan
    • Tausif Khan · Principal investigator
08

References and documents

Publications

  • Barzegari H, Khavanin A, Delirrooyfard A, Shaabani S. Intravenous furosemide vs nebulized furosemide in patients with pulmonary edema: A randomized controlled trial. Health Sci Rep. 2021 Jan 14;4(1):e235. doi: 10.1002/hsr2.235. eCollection 2021 Mar. PubMed 33490638 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for May 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Dec 2026
Primary completionEst.
May 2027
CompletionEst.
Jun 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947069
Lead sponsor
Federal Government Polyclinic - Post Graduate Medical Institute (FGPC-PGMI)
Responsible party
Muhammad Tausif Khan (Post Graduate Resident, Federal Government Polyclinic - Post Graduate Medical Institute (FGPC-PGMI)) — Principal investigator
First posted
Nov 18, 2026
Start date
Dec 2026 (estimated)
Primary completion
May 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Tausif Khan
Contact
mtausifkhan1999@gmail.com
+923110920949‬
Tausif Khan, MBBS, FCPS Trainee
principal investigator · Federal Government Polyclinic Hospital, Islamabad

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion